Patents by Inventor Earl R. Speicher

Earl R. Speicher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fluoroether compositions and methods for inhibiting their degradation in the presnce of a lewis acid
    Publication number: 20040048932
    Abstract: The present invention relates to an anesthetic composition containing a fluoroether compound and a physiologically acceptable Lewis acid inhibitor. This composition exhibits improved stability and does not readily degrade in the presence of a Lewis acid.
    Type: Application
    Filed: June 26, 2003
    Publication date: March 11, 2004
    Inventors: Christopher Bieniarz, Steve H. Chang, Keith R. Cromack, Shuyen L. Huang, Toshikazu Kawai, Manami Kobayashi, David Loffredo, Rajagopalan Raghavan, Earl R. Speicher, Honorate A. Stelmach
  • Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
    Patent number: 6677492
    Abstract: The present invention relates to an anesthetic composition containing a fluoroether compound and a physiologically acceptable Lewis acid inhibitor. This composition exhibits improved stability and does not readily degrade in the presence of a Lewis acid.
    Type: Grant
    Filed: July 3, 2002
    Date of Patent: January 13, 2004
    Assignee: Abbott Laboratories
    Inventors: Christopher Bieniarz, Steve H. Chang, Keith R. Cromack, Shuyen L. Huang, Toshikazu Kawai, Manami Kobayashi, David Loffredo, Rajagopalan Raghavan, Earl R. Speicher, Honorats A. Stelmach
  • Container for an inhalation anesthetic
    Publication number: 20030200963
    Abstract: A pharmaceutical product. The pharmaceutical product includes a container constructed from a material containing one or more of polypropylene, polyethylene, and ionomeric resins. The container defines an interior space. A volume of a fluoroether-containing inhalation anesthetic is contained in the interior space defined by the container.
    Type: Application
    Filed: April 4, 2003
    Publication date: October 30, 2003
    Inventors: Mary Jane Flament-Garcia, Keith R. Cromack, David Loffredo, Rajagopalan Raghavan, George M. Ramsay, Earl R. Speicher
  • Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid
    Publication number: 20030130359
    Abstract: The present invention relates to an anesthetic composition containing a fluoroether compound and a physiologically acceptable Lewis acid inhibitor. This composition exhibits improved stability and does not readily degrade in the presence of a Lewis acid.
    Type: Application
    Filed: July 3, 2002
    Publication date: July 10, 2003
    Inventors: Christopher Bieniarz, Steve H. Chang, Keith R. Cromack, Shuyen L. Huang, Toshikazu Kawai, Manami Kobayashi, David Loffrado, Rajagopalan Raghavan, Earl R. Speicher, Honorate A. Stelmach
  • Container for an inhalation anesthetic
    Patent number: 6558679
    Abstract: A pharmaceutical product. The pharmaceutical product includes a container constructed from a material containing one or more of polypropylene, polyethylene, and ionomeric resins. The container defines an interior space. A volume of a fluoroether-containing inhalation anesthetic is contained in the interior space defined by the container.
    Type: Grant
    Filed: December 19, 2000
    Date of Patent: May 6, 2003
    Assignee: Abbott Laboratories
    Inventors: Mary Jane Flament-Garcia, Keith R. Cromack, David Loffredo, Rajagopalan Raghavan, George M. Ramsay, Earl R. Speicher
  • Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
    Patent number: 6444859
    Abstract: The present invention relates to an anesthetic composition containing a fluoroether compound and a physiologically acceptable Lewis acid inhibitor. This composition exhibits improved stability and does not readily degrade in the presence of a Lewis acid.
    Type: Grant
    Filed: August 8, 2001
    Date of Patent: September 3, 2002
    Assignees: Abbott Laboratories, Central Glass Company LTD
    Inventors: Christopher Bieniarz, Steve H. Chang, Keith R. Cromack, Shuyen L. Huang, Toshikazu Kawai, Manami Kobayashi, David Loffredo, Rajagopalan Raghavan, Earl R. Speicher, Honorate A. Stelmach
  • Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid
    Publication number: 20020016373
    Abstract: The present invention relates to an anesthetic composition containing a fluoroether compound and a physiologically acceptable Lewis acid inhibitor. This composition exhibits improved stability and does not readily degrade in the presence of a Lewis acid.
    Type: Application
    Filed: August 8, 2001
    Publication date: February 7, 2002
    Inventors: Christopher Bieniarz, Steve H. Chang, Keith R. Cromack, Shuyen L. Huang, Toshikazu Kawai, Manami Kobayashi, David Loffredo, Rajagopalan Raghavan, Earl R. Speicher, Honorate A. Stelmach
  • Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
    Patent number: 6288127
    Abstract: The present invention relates to an anesthetic composition containing a fluoroether compound and a physiologically acceptable Lewis acid inhibitor. This composition exhibits improved stability and does not readily degrade in the presence of a Lewis acid.
    Type: Grant
    Filed: November 23, 1999
    Date of Patent: September 11, 2001
    Assignee: Abbott Laboratories & Central Glass Co LTD
    Inventors: Christopher Bieniarz, Steve H. Chang, Keith R. Cromack, Shuyen L. Huang, Toshikazu Kawai, Manami Kobayashi, David Loffredo, Rajagopalan Raghavan, Earl R. Speicher, Honorate A. Stelmach
  • Container for an inhalation anesthetic
    Publication number: 20010000729
    Abstract: A pharmaceutical product. The pharmaceutical product includes a container constructed from a material containing one or more of polypropylene, polyethylene, and ionomeric resins. The container defines an interior space. A volume of a fluoroether-containing inhalation anesthetic is contained in the interior space defined by the container.
    Type: Application
    Filed: December 19, 2000
    Publication date: May 3, 2001
    Inventors: Mary Jane Flament-Garcia, Keith R. Cromack, David Loffredo, Rajagopalan Raghavan, George M. Ramsay, Earl R. Speicher
  • Container for an inhalation anesthetic
    Patent number: 6162443
    Abstract: A pharmaceutical product. The pharmaceutical product includes a container constructed from a material containing one or more of polypropylene, polyethylene, and ionomeric resins. The container defines an interior space. A volume of a fluoroether-containing inhalation anesthetic is contained in the interior space defined by the container.
    Type: Grant
    Filed: December 4, 1998
    Date of Patent: December 19, 2000
    Assignee: Abbott Laboratories
    Inventors: Mary Jane Flament-Garcia, Keith R. Cromack, David Loffredo, Rajagopalan Raghavan, George M. Ramsay, Earl R. Speicher
  • Propofol composition
    Patent number: 6140373
    Abstract: The present invention is directed to a sterile pharmaceutical composition comprising a propofol containing oil-in-water emulsion formulation having as an antimicrobial agent, a member selected from the group consisting of benzyl alcohol and ethylene diamine tetra acetic acid; benzethonium chloride; and benzyl alcohol and sodium benzoate.
    Type: Grant
    Filed: October 23, 1998
    Date of Patent: October 31, 2000
    Assignee: Abbott Laboratories
    Inventors: Thomas May, John Hofstetter, Kathleen L. Olson, Sukumaran K. Menon, Bernard A. Mikrut, Clayton S. Ovenshire, Lawrence John Rhodes, Earl R. Speicher, James R. Waterson
  • Propofol composition
    Patent number: 6140374
    Abstract: The present invention is directed to a sterile pharmaceutical composition comprising a propofol containing oil-in-water emulsion formulation having as an antimicrobial agent, a member selected from the group consisting of benzyl alcohol and sodium ethylene diamine tetraacetate; benzethonium chloride; and benzyl alcohol and sodium benzoate.
    Type: Grant
    Filed: July 15, 1999
    Date of Patent: October 31, 2000
    Assignee: Abbott Laboratories
    Inventors: Thomas May, John Hofstetter, Kathleen L. Olson, Sukumaran K. Menon, Bernard A. Mikrut, Clayton S. Ovenshire, Lawrence John Rhodes, Earl R. Speicher, James R. Waterson
  • Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
    Patent number: 5990176
    Abstract: The present invention relates to an anesthetic composition containing a fluoroether compound and a physiologically acceptable Lewis acid inhibitor. This composition exhibits improved stability and does not readily degrade in the presence of a Lewis acid.
    Type: Grant
    Filed: January 27, 1997
    Date of Patent: November 23, 1999
    Assignees: Abbott Laboratories, Central Glass Company Ltd.
    Inventors: Christopher Bieniarz, Steve H. Chang, Keith R. Cromack, Shuyen L. Huang, Toshikazu Kawai, Manami Kobayashi, David Loffredo, Rajagopalan Raghavan, Earl R. Speicher, Honorate A. Stelmach
  • Pharmaceutical compositions containing paclitaxel
    Patent number: 5922754
    Abstract: The present invention provides novel paclitaxel formulations which may be terminally sterilized and show long term stability in water containing admixtures.
    Type: Grant
    Filed: October 2, 1998
    Date of Patent: July 13, 1999
    Assignee: Abbott Laboratories
    Inventors: Mark K. Burchett, Cynthia A. Coddington, Rajagopalan Raghavan, Earl R. Speicher
  • Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester
    Patent number: 4925860
    Abstract: Described is a stable pharmaceutical composition of 3-(hydroxymethyl-5,5-diphenylhydantoin disodium phosphate ester, the prodrug of 5,5-diphenylhydantoin (phenytoin) a commonly used drug for the treatment and management of epilepsy and other types of convulsive states. It has been found that degradation of the prodrug to phenytoin can be controlled by controlling the pH of the composition. Controlling the pH to between 8.3 to 9.4 results in the production of diphenylglycinamide as the primary degradant and minimization of degradation to phenytoin. If the pH is maintained at a lower or higher value, then the degradation pattern changes, with earlier than expected product failure.
    Type: Grant
    Filed: May 25, 1989
    Date of Patent: May 15, 1990
    Assignee: E. I. Du Pont de Nemours and Company
    Inventors: Dale E. Herbranson, Earl R. Speicher, Leonard S. Rosenberg
  • Stable pharmaceutical composition
    Patent number: 4857552
    Abstract: An injectable, aqueous pharmaceutical composition for the treatment of cardiac conditions comprising an effective amount of methyl 3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate hydrochloride (esmolol) for treating such a cardiac condition, said composition comprising about 1 mg to 250 mg of esmolol per milliliter of said injectable pharmaceutical composition; 0.01 to 0.02M buffer; said composition having a pH range of 4.5 to 5.5, the esmolol degrading in aqueous solution to produce 3-[4-(3-propionic acid)phenoxy]-1-isopropylamino-2-propanol hydrochloride, said 3-[4-(3-propionic acid)-phenoxyl]-1-isopropylamino-2-propanol hydrochloride having a pK in the pH range of said composition to thereby act as a secondary buffer to increase the buffer capacity and minimize the change in pH as degradation occurs, whereby the stability of esmolol in an aqueous composition is enhanced.
    Type: Grant
    Filed: June 8, 1988
    Date of Patent: August 15, 1989
    Assignee: E. I. du Pont de Nemours and Co.
    Inventors: Leonard S. Rosenberg, Cheryl Black, Earl R. Speicher, Dietmar Wagenknecht